Funding for this research was provided by:
National Heart, Lung, and Blood Institute (U01HL143505)
National Institute of General Medical Sciences (K23GM129661)
National Center for Advancing Translational Sciences (KL2TR002539)
Received: 3 May 2020
Accepted: 15 July 2020
First Online: 28 July 2020
Ethics approval and consent to participate
: The study was approved by the Intermountain Healthcare Institutes Review Board, reference number IRB#1050867. All human subjects provided consent to participate in this study and to have their de-identified interview results disseminated for research purposes.
: All interview participants consented to have their de-identified interview results disseminated for research purposes, including publication.
: AK, JK, DW, LA, JJ, LC, CW, JB, and CG—the authors have no competing financial or non-financial interests.IP—Dr. Peltan has research grants to the author’s institution with Asahi Kasei Pharma, Immunexpress, Inc. and Janssen Pharmaceuticals.RS—Dr. Srivastava is a physician founder of the I-PASS Patient Safety Institute. His employer, Intermountain Healthcare, owns his equity in the I-PASS Patient Safety Institute.Dr. Srivastava is supported in part by the Children’s Hospital Association for his work as executive council member of the Pediatric Research in Inpatient Settings (PRIS) network. Dr. Srivastava has received monetary awards, honorariums, and travel reimbursement from multiple academic and professional organizations for talks about pediatric hospitalist research networks and quality of care.